Practolol in treatment of angina pectoris. A double-blind trial.

Abstract

Twenty-four patients with angina pectoris entered a double-blind trial of the cardioselective beta-adrenergic blocking agent practolol. Seventeen experienced less angina and consumed fewer glyceryl trinitrate tablets when on the active preparation. There was also a decrease in the mean number of attacks suffered by patients while on practolol and a reduction in the number of glyceryl trinitrate tablets taken. These results are of statistical significance at, at least, the 5% level.

• Authors: C F George, R E Nagle, B L Pentecost
• Journal: British medical journal (Br Med J) Vol. 2 Issue 5706 Pg. 402-4 (May 16 1970) ISSN: 0007-1447 [Print] England
• PMID: 4392984 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Acetanilides
• Adrenergic beta-Antagonists
• Placebos
• Sympatholytics
• Nitroglycerin

Topics

• Acetanilides (administration & dosage, adverse effects, therapeutic use)
• Adrenergic beta-Antagonists (administration & dosage, adverse effects, therapeutic use)
• Aged
• Angina Pectoris (drug therapy)
• Clinical Trials as Topic
• Female
• Humans
• Male
• Middle Aged
• Nitroglycerin (therapeutic use)
• Placebos
• Sympatholytics (therapeutic use)